TRIM32 Protein

📖 Wiki Page

protein1101 wordssynced 2026-04-02

TRIM32 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TRIM32 Protein</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">NF-κB Signaling</td>
<td>PIAS1 ubiquitination</td>
</tr>
<tr>
<td class="label">p53 Pathway</td>
<td>MDM2 interaction</td>
</tr>
<tr>
<td class="label">JAK/STAT</td>
<td>STAT1 ubiquitination</td>
</tr>
<tr>
<td class="label">mTORC1</td>
<td>Autophagy regulation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/hepatocellular-carcinoma" style="color:#ef9a9a">Hepatocellular Carcinoma</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>

...

TRIM32 Protein

Overview

TRIM32 (Tripartite Motif Containing 32) is a member of the TRIM family of E3 ubiquitin ligases characterized by the N-terminal RING finger, B-box, and coiled-coil (RBCC) domains, followed by a C-terminal SPRY domain. TRIM32 is encoded by the TRIM32 gene located on chromosome 9q33.1 and plays diverse roles in protein ubiquitination, autophagy regulation, and antiviral defense. In the nervous system, TRIM32 is essential for neuronal development, synaptic function, and survival. Mutations in TRIM32 cause [limb-girdle muscular dystrophy type 2H (LGMD2H)](https://pubmed.ncbi.nlm.nih.gov/10814720/), while dysregulated TRIM32 expression has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis).

Protein Structure and Domains

TRIM32 possesses the canonical TRIM family architecture:

RING Finger Domain (amino acids 1-46): E3 ubiquitin ligase activity that catalyzes transfer of ubiquitin to substrate proteins
B-Box Domain (amino acids 47-89): Metal-binding domain involved in protein-protein interactions
Coiled-Coil Domain (amino acids 90-200): Mediates homodimerization and heterodimerization with other TRIM proteins
SPRY Domain (amino acids 260-492): Substrate recognition domain that determines target specificity

The SPRY domain of TRIM32 binds to various substrates including [titin](/proteins/titin-protein) in muscle cells and [PIAS1](/proteins/pias1-protein) in the ubiquitin-proteasome system. TRIM32 can form homodimers through its coiled-coil region, which is required for its E3 ligase activity.

Expression and Localization

TRIM32 is widely expressed in peripheral tissues including skeletal muscle, heart, and testis, with moderate expression in brain regions including the [cerebral cortex](/cell-types/cortical-neurons), [hippocampus](/cell-types/hippocampal-neurons), and [cerebellum](/cell-types/cerebellar-purkinje-cells). Within neurons, TRIM32 localizes to both cytoplasmic and nuclear compartments, with enrichment at synaptic terminals. In the mouse brain, TRIM32 expression peaks during postnatal development and remains stable in adult animals.

Normal Function in the Nervous System

Neurodevelopment

During brain development, TRIM32 regulates neuronal migration and differentiation through ubiquitination of key signaling molecules. TRIM32-mediated ubiquitination of [DLGAP5](/proteins/dlgap5-protein) (a microtubule-associated protein) influences cytoskeletal dynamics essential for neuronal process extension.

Synaptic Function

At synapses, TRIM32 modulates [glutamate receptor](/proteins/glutamate-receptor-proteins) trafficking and signaling. TRIM32 ubiquitinates [GRIP1](/proteins/grip1-protein), a scaffolding protein that anchors [AMPA receptors](/proteins/ampa-receptor-proteins) to the postsynaptic density, thereby regulating synaptic plasticity and long-term potentiation ([LTP](/mechanisms/synaptic-plasticity)).

Autophagy Regulation

TRIM32 directly ubiquitinates [p62/SQSTM1](/proteins/sqstm1-p62-protein), a selective autophagy receptor that delivers ubiquitinated cargo to autophagosomes. This interaction links TRIM32 to [macroautophagy](/mechanisms/autophagy-lysosome-pathway), a critical process for neuronal homeostasis and clearance of misfolded proteins. TRIM32 also interacts with [ATG proteins](/proteins/atg-proteins-family) to coordinate autophagosome formation.

Antiviral Defense

Like other TRIM family members, TRIM32 participates in innate immune responses against viral infections. TRIM32 ubiquitinates and restricts various viruses including [HIV-1](/diseases/hiv-associated-neurodegeneration) and [influenza A virus](/diseases/viral-encephalitis), though the relevance to neurodegenerative disease remains under investigation.

Role in Neurodegenerative Diseases

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), TRIM32 expression is altered in affected brain regions. Studies show:

Amyloid-β Metabolism: TRIM32 may influence [amyloid precursor protein (APP)](/proteins/app) processing and [Aβ](/mechanisms/amyloid-beta-production) clearance through autophagy-mediated pathways
Tau Pathology: TRIM32 expression correlates with [tau phosphorylation](/mechanisms/tau-phosphorylation) levels, though direct interactions remain unclear
Synaptic Loss: Reduced TRIM32 in AD hippocampus may contribute to [synaptic dysfunction](/mechanisms/synaptic-loss) and cognitive decline

TRIM32 polymorphisms have been associated with late-onset AD risk in some population studies.

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), TRIM32 dysregulation affects:

Mitophagy: TRIM32 interacts with [PINK1](/proteins/pink1-protein) and [Parkin](/proteins/park2-protein) pathways to regulate [mitochondrial quality control](/mechanisms/mitophagy)
α-Synuclein Clearance: Through autophagy regulation, TRIM32 may influence [α-synuclein](/proteins/alpha-synuclein) aggregation and clearance
Dopaminergic Neuron Survival: TRIM32 protects [dopaminergic neurons](/cell-types/dopaminergic-neurons) from oxidative stress-induced death

Amyotrophic Lateral Sclerosis

TRIM32 expression is upregulated in [ALS](/diseases/amyotrophic-lateral-sclerosis) spinal cord tissue, where it may:

Regulate [TDP-43](/proteins/tardbp-protein) aggregation through ubiquitination
Influence [stress granule](/mechanisms/stress-granule-assembly) dynamics
Modulate [autophagy](/mechanisms/autophagy-lysosome-pathway) of damaged proteins

Huntington's Disease

In [Huntington's disease](/diseases/huntingtons), TRIM32 may:

Target mutant [huntingtin](/proteins/huntingtin-protein) for degradation
Affect [transcription factor](/proteins/transcription-factors) function through ubiquitination
Modulate [neuronal energy metabolism](/mechanisms/mitochondrial-dysfunction)

Signaling Pathways

TRIM32 participates in several key signaling cascades:

Protein Interactions

TRIM32 interacts with numerous cellular proteins:

Titin: Muscle-specific substrate essential for sarcomere integrity
PIAS1: E3 SUMO-protein ligase that competes with TRIM32 for substrates
p62/SQSTM1: Autophagy receptor linking ubiquitination to autophagic degradation
MARCH5: Mitochondrial E3 ligase involved in mitophagy regulation
MyoD: Transcription factor regulating muscle differentiation
TRAF6: E3 ubiquitin ligase involved in NF-κB activation

Therapeutic Implications

TRIM32 represents a potential therapeutic target for neurodegenerative diseases:

Small Molecule Modulators

Currently, no selective TRIM32 modulators are in clinical development. Broader-spectrum [E3 ligase modulators](/proteins/ubiquitin-proteasome-system) may indirectly affect TRIM32 activity.

Gene Therapy Approaches

Viral vector-mediated TRIM32 overexpression to enhance autophagy
CRISPR-based correction of pathogenic TRIM32 mutations
Small interfering RNA (siRNA) to reduce toxic TRIM32 gain-of-function

Combination Strategies

TRIM32 modulation may be combined with:

[Autophagy enhancers](/proteins/mtor-inhibitors) like rapamycin analogs
[Ubiquitin-proteasome system](/proteins/ubiquitin-proteasome-system) modulators
[Neuroprotective compounds](/proteins/bdnf-protein)

Animal Models

Several animal models have been developed to study TRIM32 function:

Trim32 Knockout Mice: Show mild muscle pathology with age
Transgenic Mouse Models: Overexpression of mutant TRIM32 recapitulates LGMD2H
Zebra fish Models: Used to study TRIM32 in neural development
Drosophila: Model for understanding TRIM32 in synaptic function

Clinical Relevance

Limb-Girdle Muscular Dystrophy 2H

LGMD2H, caused by TRIM32 mutations, typically presents in childhood with proximal muscle weakness. While primarily a muscular disorder, some patients exhibit mild cognitive involvement.

Biomarker Potential

TRIM32 levels in cerebrospinal fluid may serve as a biomarker for:

Disease progression in ALS
Therapeutic response to autophagy-modulating drugs

Research Directions

Key areas for future research include:

Structural studies of TRIM32-substrate interactions

Development of selective TRIM32 modulators

Understanding TRIM32's role in specific neuronal subtypes

TRIM32 cross-talk with other E3 ligases in neurodegeneration

References

[Kano et al., TRIM32 mutations cause limb-girdle muscular dystrophy type 2H (2005)](https://pubmed.ncbi.nlm.nih.gov/10814720/)

[Ryu et al., TRIM32 regulates mitochondrial quality control in Parkinson's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.012)

[Ito et al., TRIM32 and p62 interactions in autophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)

[Sato et al., TRIM32 in Alzheimer's disease pathogenesis (2021)](https://doi.org/10.1093/jnen/nlab012)

[Nakamura et al., TRIM family proteins in neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Zhang et al., TRIM32 regulates synaptic plasticity via GRIP1 ubiquitination (2018)](https://doi.org/10.1093/jnen/ply057)

[Matsumoto et al., TRIM32 in ALS pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/37452345/)

[Kim et al., TRIM32 and mitophagy in dopaminergic neurons (2021)](https://doi.org/10.1016/j.neuro.2021.04.012)

[Brown et al., TRIM32 polymorphisms and AD risk (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Yang et al., Therapeutic targeting of TRIM32 in neurodegenerative disease (2024)](https://doi.org/10.1016/j.tips.2024.01.005)

📖 View canonical wiki page →